Mifepristone dominates U.S. abortion care landscape
Mifepristone is now the most frequently used abortion method across the U.S.
Event / Politics
Mifepristone FDA Safety Review
The FDA announced an extended safety review of mifepristone (abortion pill) ordered by Health Secretary RFK Jr., with completion expected by March 2027. The review will assess potential new restrictions on telehealth and mail delivery access, amid legal challenges and medical expert testimony.
3 reported locations
Daily activity
4 articles0 articles
2026-10-09 to 2026-10-29 · UTC publication dates
Coverage begins 9 Oct, 02:07 UTC
Follow the documented timeline or explore the related reporting.
What happened
FDA approved mifepristone as safe and effective for 26 years
The FDA first approved mifepristone in 2000 and has repeatedly reaffirmed the pill's safety and effectiveness over the subsequent 26 years. The agency has progressively eased restrictions on the drug, including eliminating a requirement that it be dispensed in person. Hundreds of peer-reviewed studies have confirmed the drug's safety profile, with less than 0.5% of women experiencing serious adverse reactions.
FDA safety review of mifepristone abortion pill will continue into 2027
The Food and Drug Administration announced that its ongoing safety review of mifepristone, the nation's primary abortion pill, will extend into 2027. The FDA expects to complete a safety study by mid-December 2026, with a final report on findings expected no later than March 2027. The review was ordered by Health Secretary Robert F. Kennedy Jr. and will examine safety data from approximately 100,000 women who took mifepristone, comparing it to surgical abortion outcomes through 10 weeks of gestation.
Supreme Court blocks changes to mifepristone pending court case resolution
The Supreme Court has blocked any changes to mifepristone's regulations until it reviews the case brought by Louisiana challenging the FDA's telehealth provisions for the abortion pill. A federal appeals court had previously ruled in May to reinstate a requirement for in-person dispensing, but the Supreme Court stayed that decision while the litigation continues.
Mifepristone is most common abortion method in the United States
The two-drug regimen of mifepristone combined with misoprostol represents the most common form of abortion in the United States. This medication-based approach has become increasingly accessible through telehealth and mail delivery.
FDA will reconsider mail delivery and telehealth access rules for mifepristone
The FDA stated that it plans to re-evaluate its 2023 decision to allow mifepristone to be prescribed online and dispensed through mail delivery. The agency will analyze new safety data and may consider views from patients, providers, pharmacists, and additional studies not previously evaluated. The decision on whether to restrict telehealth or mail access to the drug will be made following completion of the safety review.
Louisiana lawsuit challenges FDA's mail-delivery policy for abortion pill
The state of Louisiana filed a lawsuit challenging the FDA's decision to allow mifepristone to be dispensed through mail delivery, arguing it undermines the state's abortion ban. The case originally involved a woman alleging her boyfriend ordered abortion pills and forced her to take them. The lawsuit is one of several state cases related to mifepristone winding through federal courts.
Trump administration pressures FDA to restrict mifepristone access
Since President Donald Trump returned to the White House, anti-abortion groups and their allies in Congress have pushed the administration to revisit mifepristone regulations in hopes of restricting its use. Health Secretary Robert F. Kennedy Jr. ordered the safety review. Senior Republicans, including Senator Bill Cassidy of Louisiana, have pressured the Trump administration to tighten access to the drug.
FDA considers multiple petitions proposing changes to mifepristone prescribing rules
In addition to the safety study, the FDA is considering petitions that propose changes to how mifepristone is prescribed and distributed. These petitions may address prescriber qualifications, delivery methods, and other regulatory aspects of the drug's availability.
5th Circuit Court questions Louisiana's legal standing in mifepristone case
A three-judge panel from the 5th U.S. Circuit Court of Appeals questioned the merits of Louisiana's lawsuit challenging FDA oversight of mifepristone, including whether the state has legal standing to challenge federal drug regulation. The court's questioning occurred in the month prior to the FDA's October status update.
FDA to use data mining to assess unknown mifepristone safety concerns
The FDA announced it will employ a statistical data mining method to discover unknown safety concerns with mifepristone. The data comes from an electronic database that collects medical injury and drug side effect reports from major health networks and insurers across the country.
Anti-abortion group criticizes FDA review timeline as inadequate
Gavin Oxley of Americans United for Life, an anti-abortion organization, criticized the FDA's decision to extend the safety review into 2027 as a lack of true leadership. Oxley stated the Trump administration appears uninterested in mitigating what he characterized as harms from the abortion pill.
Read the coverage
2 alternative perspectives
Anti-abortion advocates challenge FDA review scope and timeline
Anti-abortion advocates challenge FDA review scope for mifepristone regulations.
Courts block mifepristone access changes as legal battles intensify
Supreme Court blocks mifepristone changes as Louisiana lawsuit and standing questions proceed through courts.
FDA extends mifepristone review into 2027, considers access restrictions
FDA extends mifepristone safety review into 2027 while reconsidering access restrictions.